site stats

Ikena therapeutics

Web7 mrt. 2024 · Ikena is advancing IK-930 both as a monotherapy in patients with Hippo pathway mutated cancers and in combination with other approved targeted therapies to … WebBackground. NTRK fusions are actionable biomarkers with efficient and well tolerated TRKis. Clinical profile and outcomes of pts with NTRK+ tumours receiving non-TRKi SoC are unknown and the prognosis of NTRK+ pts vs pts with NTRK fusion-negative (NTRK–) tumours is not well known.

Ikena Oncology to Present Preclinical Findings on IK-930, a

WebKyn Therapeutics is advancing development programs with targets strongly implicated in immunosuppression across a range of tumor types and via multiple immune cell effects. … Web2 nov. 2024 · Ikena is developing IK-930 as a potential targeted therapy for patients with cancers that exhibit genetic alterations across the Hippo pathway. IK-930 is designed to selectively bind TEAD and to disrupt TEAD-dependent transcription of key genes involved in cancer progression, metastases, and therapeutic resistance. cleaning carpets after painting a room https://jcjacksonconsulting.com

Ikena Oncology - Atlas Venture

WebCompanies include: Tango Therapeutics, Ikena Oncology, Intellia Therapeutics, Solid Bio, Mersana Therapeutics, and Shire. Responsible for full life cycle recruiting for all areas of … WebPatient-directed oncology therapies across pathways relevant in tumor and immune cells Ikena is a targeted oncology company focused on developing novel cancer therapies … WebIkena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms … Jun 2024 From Ikena Oncology. TRIAL IN PROGRESS: A Phase 1a/b Open Label … At Ikena™, our team is collaborative, passionate about making a difference in … Ikena Oncology is focused on developing novel therapies targeting key signaling … Ikena Oncology Investors Ikena Oncology 645 Summer Street, Suite 101 Boston, MA 02210. Company. … Ikena Oncology may also disclose Aggregate Data in order to describe our … However, Ikena will not release your name or otherwise publicize the fact that you … Ikena is committed to making our website accessible to everyone. We have built … downtown wadsworth

Repare Synthetic Lethality Precision Oncology Leadership

Category:Atalanta Therapeutics » Home

Tags:Ikena therapeutics

Ikena therapeutics

Pipeline Ikena Oncology

Web28 nov. 2024 · Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance. 10/26/2024. Ikena Oncology, Inc. today announced a poster presentation highlighting preclinical data on the company’s novel TEAD inhibitor, IK-930, at the 34th EORTC-NCI … WebFounded Date 2014. Founders Sofie Qiao. Operating Status Active. Last Funding Type Series C. Legal Name Vivace Therapeutics, Inc. Company Type For Profit. Contact Email [email protected]. Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel …

Ikena therapeutics

Did you know?

WebDescription. Developer of an immuno-metabolism therapy technology designed to translate high-impact science into medicines for patients. The company's technology is meant for implementation in human clinical studies for non-oncology indications, enabling doctors to treat cancer patients in a better and hassle-free way. Web28 nov. 2024 · Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced that management will participate in a …

WebIkena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is …

Web2 nov. 2024 · Preclinical research, including data presented by Ikena at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2024, suggests that IK-930 is a ... WebOur Pipeline. As we evolve with our science, our multifaceted approach builds a robust pipeline of patient direct therapies. At Ikena™, we are advancing a portfolio of targeted …

Web26 mrt. 2024 · Noam Galai/Getty Images. This week began with four biopharma companies announcing intentions to become publicly traded companies and it’s ending with three companies making their debut on the Nasdaq. This morning, two of those companies, Ikena Oncology and Design Therapeutics, join Edgewise Therapeutics by trading on the …

Web8 dec. 2024 · Michelle Zhang, Ph.D., joined Ikena (then Kyn Therapeutics) in 2016 as Vice President, Research and Development and was later promoted to Senior Vice President, ... downtown wakefield riWebIkena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed therapies for cancer patients, by understanding what drives their disease. Ikena leverages core capabilities in oncology drug discovery, translational sciences and clinical development to build a next generation ... downtown waco tx restaurantsWeb7 okt. 2024 · Pioneering treatments for neurodegenerative diseases. Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders’ groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source. Atalanta's. branched siRNA. cleaning carpet products greenWeb3 dec. 2024 · Ikena is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading … downtown wadsworth eventsWeb7 mrt. 2024 · Dr. Jeff Ecsedy, Ikena’s Chief Development Officer, will present data supporting the potential of IK-930 as a clinical agent during a minisymposium on experimental and molecular cancer therapeutics. cleaning carpet products topWebIkena is employing a robust, biomarker strategy by analyzing blood, tumor and urine biomarkers relevant to T cell checkpoint inhibitors and EP4 signaling. Ikena expects to … downtown wadsworth restaurantsWebCedilla’s conditional inhibitors are small molecules that are unlocking historically undruggable cancer targets for therapeutic development. Our asset-by-asset approach is not one-size-fits-all. We start by developing a deep understanding of the disease biology and contextual biochemistry of the target. We then deploy cutting-edge ... cleaning carpets companies asbury park